These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32429592)

  • 1. Medication Management after Bariatric Surgery: Providing Optimal Patient Care.
    Porat D; Dahan A
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32429592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of COVID-19 Patients Post-Bariatric Surgery: Issues for Consideration.
    Azran C; Porat D; Dahan A; Dicker D
    J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32878333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
    Darwich AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A
    J Pharm Pharmacol; 2012 Jul; 64(7):1008-24. PubMed ID: 22686346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations.
    Azran C; Wolk O; Zur M; Fine-Shamir N; Shaked G; Czeiger D; Sebbag G; Kister O; Langguth P; Dahan A
    Obes Rev; 2016 Nov; 17(11):1050-1066. PubMed ID: 27335140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication and nutrient administration considerations after bariatric surgery.
    Miller AD; Smith KM
    Am J Health Syst Pharm; 2006 Oct; 63(19):1852-7. PubMed ID: 16990631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DRUG THERAPY FOLLOWING BARIATRIC SURGERY: EXAMINATION OF POTENTIAL IMPACT AND CLINICAL RECOMMENDATIONS].
    Azran C; Dahan A
    Harefuah; 2017 Jan; 156(1):31-37. PubMed ID: 28530310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the Unpredictable: Mechanistic Analysis and Clinical Recommendations for Lamotrigine Treatment after Bariatric Surgery.
    Porat D; Azran C; Kais H; Dahan A
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RYGB and Drug Disposition: How to Do Better? Analysis of Pharmacokinetic Studies and Recommendations for Clinical Practice.
    Hachon L; Declèves X; Faucher P; Carette C; Lloret-Linares C
    Obes Surg; 2017 Apr; 27(4):1076-1090. PubMed ID: 28124236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered drug disposition following bariatric surgery: a research challenge.
    Greenblatt HK; Greenblatt DJ
    Clin Pharmacokinet; 2015 Jun; 54(6):573-9. PubMed ID: 25782774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: The nutritional and pharmacological consequences of obesity surgery.
    Stein J; Stier C; Raab H; Weiner R
    Aliment Pharmacol Ther; 2014 Sep; 40(6):582-609. PubMed ID: 25078533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ADJUSTMENTS IN THE ORAL DRUG TREATMENT OF BARIATRIC PATIENTS].
    Mahler I; Roder D
    Harefuah; 2017 Jan; 156(1):29-30. PubMed ID: 28530311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects.
    Azran C; Porat D; Fine-Shamir N; Hanhan N; Dahan A
    Surg Obes Relat Dis; 2019 Feb; 15(2):333-341. PubMed ID: 30704913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Contraceptives after Bariatric Surgery.
    Schlatter J
    Obes Facts; 2017; 10(2):118-126. PubMed ID: 28433989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug absorption in bariatric surgery patients: A narrative review.
    Alalwan AA; Friedman J; Alfayez O; Hartzema A
    Health Sci Rep; 2022 May; 5(3):e605. PubMed ID: 35509385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term pharmacotherapy considerations in the bariatric surgery patient.
    Bland CM; Quidley AM; Love BL; Yeager C; McMichael B; Bookstaver PB
    Am J Health Syst Pharm; 2016 Aug; 73(16):1230-42. PubMed ID: 27354038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.
    Dahan A; Beig A; Lindley D; Miller JM
    Adv Drug Deliv Rev; 2016 Jun; 101():99-107. PubMed ID: 27129443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.
    Brill MJ; van Rongen A; van Dongen EP; van Ramshorst B; Hazebroek EJ; Darwich AS; Rostami-Hodjegan A; Knibbe CA
    Pharm Res; 2015 Dec; 32(12):3927-36. PubMed ID: 26202517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic effects of bariatric surgery.
    Edwards A; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):130-6. PubMed ID: 22190251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.